This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Xenoport's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Now turning to Arbaclofen Placarbil or AP, we expect completion of enrollment of the pivotal Phase 3 trial for the treatment of spasticity in MS patients this fall and topline results in Q1 of 2013. Patients who complete this trial are eligible to continue AP treatment in the six-month open-label safety study.

As I mentioned in our last call, we initiated communication with the FDA to discuss the possible need to modify our trials to ensure that we meet the FDA's safety data requirements of 150 subjects with six months and 100 subjects with nine months of AP exposure.

We now have FDA agreement to enroll subjects directly into the open-label safety study, allowing directly enroll subjects to stay on AP for nine months. We believe that this was a good outcome since it avoided potential modification of the Phase 3 efficacy protocol for which we have a special protocol assessment and should allow us to keep our timeline of the potential filing of the NDA in the second half of 2013.

In June, we also had a productive End-of-Phase 2 meeting with the FDA, regarding our L-Dopa prodrug 279. As I mentioned last quarter, we have discussed the data with of our Phase 2 279 trial with an advisory board comprised of Parkinson's disease experts. They indicated they believe that the pharmacokinetics of 279 compared to Sinemet were impressive, encouraged us to find a way and continue development of product candidate.

We also took note of the results of the Phase 3 trial of the intravenous infusion pump Duodopa, that were presented at AAN earlier this year, where the maximum benefit of Duodopa over optimized Sinemet was observed at 10 to 12 weeks. I’ll remind you that the length of treatment of the optimized doses of 279 and Sinemet in the randomize phase of our Phase 2 trial was only two weeks.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs